Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

43.18 -0.59 (-1.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,775,237
Open 43.57
Bid (Size) 43.20 (100)
Ask (Size) 43.50 (200)
Prev. Close 43.77
Today's Range 43.12 - 43.79
52wk Range 43.09 - 53.36
Shares Outstanding 1,250,690,553
Dividend Yield 5.12%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Recursion (RXRX) Q1 2026 Earnings Transcript ↗
Recursion (RXRX) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
Sanofi (NASDAQ:SNY) Emerges as a Decent Value Pick with Strong Fundamentals ↗
Via Chartmill

Performance

YTD
-10.5%
-10.5%
1 Month
-7.8%
-7.8%
3 Month
-9.1%
-9.1%
6 Month
-12.8%
-12.8%
1 Year
-17.4%
-17.4%

More News

Read More
Sanofi (NASDAQ:SNY): A High-Yield Dividend Stock with Strong Fundamentals and a 5.26% Payout ↗
Via Chartmill
News headline image
Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't? ↗
Via The Motley Fool
Sanofi ADR (NASDAQ:SNY) Presents a Classic Value Investment Case ↗
Via Chartmill
Sanofi (NASDAQ:SNY) Emerges as a Top Dividend Stock from Methodical Screening ↗
Via Chartmill
News headline image
Giants Costco, Sanofi, and SAP Raise Dividends by Over 10% ↗
Via MarketBeat
News headline image
3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery ↗
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth ↗
Via The Motley Fool
News headline image
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
Via MarketMinute
Topics Intellectual Property
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
Via MarketMinute
Topics Economy World Trade
News headline image
Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring
Via MarketMinute
Topics Economy Government Lawsuit
News headline image
Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution
Via MarketMinute
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
Via Finterra
Topics Initial Public Offering
News headline image
Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly
Via MarketMinute
News headline image
AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results
Via MarketMinute
Topics Intellectual Property
News headline image
Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
Via MarketMinute
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
Via Finterra
Topics Economy Initial Public Offering
News headline image
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? ↗
Via The Motley Fool
News headline image
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
Via MarketMinute
Topics Artificial Intelligence Initial Public Offering Stocks
News headline image
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
Via Finterra
Topics Economy
News headline image
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗
Via Stocktwits
News headline image
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
Via Finterra
Topics Initial Public Offering Intellectual Property

Frequently Asked Questions

Is Sanofi - American Depositary Shares publicly traded?
Yes, Sanofi - American Depositary Shares is publicly traded.
What exchange does Sanofi - American Depositary Shares trade on?
Sanofi - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Sanofi - American Depositary Shares?
The ticker symbol for Sanofi - American Depositary Shares is SNY on the Nasdaq Stock Market
What is the current price of Sanofi - American Depositary Shares?
The current price of Sanofi - American Depositary Shares is 43.18
When was Sanofi - American Depositary Shares last traded?
The last trade of Sanofi - American Depositary Shares was at 05/07/26 04:00 PM ET
What is the market capitalization of Sanofi - American Depositary Shares?
The market capitalization of Sanofi - American Depositary Shares is 54.00B
How many shares of Sanofi - American Depositary Shares are outstanding?
Sanofi - American Depositary Shares has 54B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.